Answers are grounded in this paper and cite their sources.
Resistance to PD-1–based immunotherapy remains a major challenge in cancer treatment, especially in immunologically “cold” tumors characterized by T-cell exclusion and impaired T-cell effector function. Mechanical processes impact T-cell activity, and mechanical perturbations may represent a distinct mode of immune suppression. Here, we identified CD209, a myeloid-expressed C-type lectin receptor, as a mechanosuppressive regulator of antitumor T-cell immunity. CD209 was selectively enriched in tumor-infiltrating M2-like macrophages and monocytes, and elevated CD209 expression was associated with poor clinical response to PD-1 blockade and immune dysfunction and exclusion across multiple cancer types. Mechanistically, CD209 directly engaged ICAM-2 on T cells and activated ROCK1–ERM signaling. This interaction increased T-cell cortical stiffness, destabilized T cell–antigen presenting cell interactions, and attenuated T-cell receptor signaling. Blocking the CD209–ICAM-2–ERM pathway restored T-cell activation and promoted CD8+ T-cell infiltration and effector function in both in vivo mouse models and ex vivo human tumor systems. Importantly, CD209 blockade enhanced the response to PD-1 inhibition and overcame resistance to PD-1–based immunotherapy in refractory and immunologically “cold” tumor models. Together, these findings define a myeloid-derived mechanical immune checkpoint and reveal T-cell mechanosuppression as a targetable mechanism of tumor immune evasion and immunotherapy resistance.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: